Related Experiment Video

Updated: Jul 13, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

Optimal platelet inhibition in patients undergoing PCI: data from the Multicenter Registry of High-Risk Percutaneous

H M Mardikar1, M S Hiremath, David J Moliterno

  • 1Spandan Heart Institute, Nagpur, India.

American Heart Journal
|July 24, 2007
PubMed

Insights

High-dose tirofiban achieved greater platelet inhibition than eptifibatide in high-risk PCI patients. Clopidogrel enhanced inhibition at 24 hours, not acutely with glycoprotein IIb/IIIa inhibitors.

Area of Science:

  • Cardiology
  • Pharmacology
  • Interventional Cardiology

Background:

  • Optimal platelet inhibition is crucial for preventing ischemic events during percutaneous coronary intervention (PCI).
  • Comparing antiplatelet regimens is essential for high-risk PCI patients.

Purpose of the Study:

  • To compare the efficacy of tirofiban and eptifibatide, with or without clopidogrel, in achieving optimal platelet inhibition.
  • To evaluate different antiplatelet strategies in patients undergoing elective high-risk PCI.

Main Methods:

  • A randomized open-label study involving 120 patients across 3 Indian heart centers.
  • Patients were assigned to receive tirofiban, eptifibatide, tirofiban + clopidogrel, or eptifibatide + clopidogrel.
  • Platelet aggregation inhibition (IPA) was the primary outcome, measured at 10 minutes, 6-8 hours, and 24 hours post-treatment.

Main Results:

  • High-dose tirofiban demonstrated significantly higher IPA at 10 minutes (95.88% vs 91.22%) and 6-8 hours (93.11% vs 85.45%) compared to eptifibatide.
  • More patients achieved >95% IPA with the high-dose tirofiban regimen.
  • Clopidogrel addition did not acutely increase IPA from intravenous glycoprotein IIb/IIIa inhibitors but showed an effect at 24 hours.

Conclusions:

  • High-dose tirofiban provides superior platelet inhibition compared to eptifibatide in high-risk PCI patients.
  • The combination of clopidogrel with glycoprotein IIb/IIIa inhibitors shows a delayed benefit in platelet inhibition.
  • These findings support optimizing antiplatelet therapy for improved outcomes in PCI procedures.
Abstract

More Related Videos

Microfluidics in Assessing Platelet Function06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...